• Adaptimmune's ROIC stands at -58.52%, indicating challenges in generating returns that exceed its cost of capital.
• Affimed N.V. shows a significantly lower efficiency in using capital with a ROIC of -244.61%.
• Cellectis S.A. has the highest ROIC to WACC ratio among peers, suggesting it is closer to balancing its returns with its cost of capital.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a biotechnology company focused on developing T-cell therapies for cancer treatment. The company aims to harness the power of the immune system to target and destroy cancer cells. In the competitive landscape, Adaptimmune faces peers like Affimed N.V., Cellectis S.A., MacroGenics, Inc., and Atara Biotherapeutics, Inc., all of which are also engaged in innovative cancer therapies.

In evaluating Adaptimmune's financial performance, the Return on Invested Capital (ROIC) and Weighted Average Cost of Capital (WACC) are crucial metrics. Adaptimmune's ROIC stands at -58.52%, while its WACC is 6.30%. This results in a ROIC to WACC ratio of -9.30, indicating that the company is not currently generating returns that exceed its cost of capital.

Comparatively, Affimed N.V. has a significantly lower ROIC of -244.61% and a WACC of 9.83%, leading to a ROIC to WACC ratio of -24.88. This suggests that Affimed is even less efficient in using its capital compared to Adaptimmune. Similarly, Atara Biotherapeutics, with a ROIC of -94.43% and a WACC of 7.76%, has a ROIC to WACC ratio of -12.16, also indicating inefficiency in capital utilization.

Cellectis S.A. emerges as the peer with the highest ROIC to WACC ratio of -1.85, despite a negative ROIC of -26.77% and a WACC of 14.44%. This suggests that Cellectis is closer to achieving a balance between its returns and cost of capital compared to its peers. MacroGenics, with a ROIC of -57.98% and a WACC of 11.46%, has a ROIC to WACC ratio of -5.06, placing it in a better position than Adaptimmune but still facing challenges in capital efficiency.

Overall, the analysis highlights that all companies, including Adaptimmune, are struggling with negative ROIC values, indicating a need for improved capital management to enhance returns relative to their cost of capital.